215 related articles for article (PubMed ID: 2957052)
1. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of medroxyprogesterone acetate from three oral dosage formulations.
Stalker DJ; Welshman IR; Pollock SR
Clin Ther; 1992; 14(4):544-52. PubMed ID: 1388093
[TBL] [Abstract][Full Text] [Related]
3. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
[TBL] [Abstract][Full Text] [Related]
4. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
[TBL] [Abstract][Full Text] [Related]
5. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
6. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
[TBL] [Abstract][Full Text] [Related]
7. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
8. Effect of injection volume on the bioavailability of sterile medroxyprogesterone acetate suspension.
Wright CE; Antal EJ; Gillespie WR; Albert KS
Clin Pharm; 1983; 2(5):435-8. PubMed ID: 6226473
[TBL] [Abstract][Full Text] [Related]
9. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
Flamm J; Spona J
Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
[TBL] [Abstract][Full Text] [Related]
11. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
12. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
Husslein P; Egarter C; Eppel W; Salzer H; Spona J
Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
[TBL] [Abstract][Full Text] [Related]
13. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
[TBL] [Abstract][Full Text] [Related]
14. [Effect of medroxyprogesterone acetate on the cell kinetics in primary breast cancer].
Doihara H; Takashima S; Saeki H; Takiyama W; Kurita A; Soga H; Tanada M; Yokoyama N; Moriwaki S
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2057-62. PubMed ID: 2145805
[TBL] [Abstract][Full Text] [Related]
15. The bioavailability of an orally administered medroxyprogesterone acetate suspension.
Antal EJ; Gillespie WR; Albert KS
Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):257-9. PubMed ID: 6222996
[TBL] [Abstract][Full Text] [Related]
16. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
17. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
18. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
19. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
[TBL] [Abstract][Full Text] [Related]
20. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
